U.S. Markets closed

Accuray Incorporated (ARAY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0500-0.0800 (-3.76%)
At close: 04:00PM EDT
2.0500 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.1300
Bid2.0300 x 3100
Ask2.2500 x 1800
Day's Range2.0350 - 2.1000
52 Week Range1.7000 - 5.9300
Avg. Volume598,030
Market Cap186.384M
Beta (5Y Monthly)1.86
PE Ratio (TTM)41.00
EPS (TTM)0.0500
Earnings DateApr 25, 2022 - Apr 29, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.83
  • PR Newswire

    Dr. Seth Blacksburg Joins Accuray as VP, Chief Medical Officer Americas Region

    Accuray Incorporated (NASDAQ: ARAY) announced today that Seth Blacksburg, M.D., MBA has joined the company as vice president, chief medical officer for the Americas (North and South America) region. Dr. Blacksburg will be responsible for bringing the strategic clinical insights, real-world experience and voice of the customer necessary to help drive the continued commercial growth of the region. He will report to Mike Leischer, Accuray president and general manager for the Americas region.

  • Zacks

    Accuray's (ARAY) Latest Collaboration to Improve Patient Care

    Accuray (ARAY) partners with Genolier Innovation Hub to unite companies from the MedTech, pharma and biosciences sectors with physicians and scientists for better patient outcomes.

  • PR Newswire

    Accuray Partners with Swiss-based Genolier Innovation Hub to Bring Medical and Technological Advances to Patients Faster

    Accuray Incorporated (NASDAQ: ARAY) announced today the company is joining forces with Genolier Innovation Hub, a fully-owned subsidiary of AEVIS VICTORIA SA (SWX: AEVS), in support of a unique new approach to improving patient care. Genolier Innovation Hub will unite companies from the medtech, pharma and biosciences sectors, physicians and scientists, under one roof, with the goal of bringing medical and technological advances to patients faster. The Hub is expected to open in early 2024.